Table 3.

Pathways tested on real-time experiments.

Pathway	Drug activator (A)/inhibitor (I)	Highest dose tested	Time of significant effect	HepG2		HuH7
				Effect	IC50 (μM)	Effect	IC50 (μM)
AMPK	AICAR (A)	2 mM	24 hr	−	3 10−3	−	1.1 10−3
	Compound C (I)	40 μM	24 hr	No effect		−	3.3 10−5
JAK1	Butein (I)	50 μM	24 hr	−	2 10−5	−	Nd
JNK	SP600125 (I)	100 μM	24 hr	−	1.8 10−5	−	2.2 10−5
LKB1	Oligomycin (A)	2 mM	48 hr	−	3 10−7	−	2.5 10−7
	Metformin (A)	10 mM	24 hr	−	7 10−6	−	8 10−4
Mek1/2	U0126 (I)	250 μM	1 hr	−	1.1 10−5	−	Nd
mTOR	Rapamycin (I)	200 nM	48 hr	No effect		No effect
Mitochondrial apoptosis	GSH (A)	10 μM	24 hr	−	10−6	−	1.3 10−4
NFκB p65	Wedelolactone (I)	10 μM	24 hr	−	0.8 10−5	−	10−5
NOX	VAS2780 (I)	50 μM	1 hr	−	5 10−5	−	1.8 10−5
P38MAPK	SD169 (I)	300 μM	24 hr	+	9.4 10−5	No effect
P42/44	A6355 (I)	90 μM	1 hr	−	−	−	−
PKA	KT5720 (I)	20 μM	48 hr	+	1.1 10−4	+	Nd
PKC	P3115 (I)	50 μM	1 hr	5 10−6	−	−	Nd
Pi3K	LY294002 (I)	50 μM	48 hr	−	3.3 10−5	−	3 10−5
PPARA	GW6471 (I)	1 mM	1 hr	−	5.7 10−4	−	4 10−4

AMPK, 5′-AMP-activated protein kinase; AICAR: 5-aminoimidazole-4-carboxamide ribonucléotide; GSH: reduced glutathione; JAK1: Janus kinase 1; JNK: Jun-NH2 kinase; LKB1: serine/threonine kinase 11; NFκBp65: nuclear factor kappa B p65 subunit; NOX: NADPH oxidases; P38MAPK: P38 mitogen-activated kinase; Pi3K: Pi3 kinase; PKA: protein kinase AMPc-dependant; PKC, protein kinase C; and PPARA, peroxisome-proliferator activated receptor alpha.